tbuckley/cabot-search huggingface dataset:
Combined chemotherapy and surgery for metastatic gallbladder cancer improve median survival
Authors: J. O. Gallardo, B. Rubio, J. C. Díaz, F. Maluenda
Journal: Journal of Clinical Oncology (2006)

14136 Background: Metastatic gallbladder cancer (MGBC) is a rapidly progressive disease, orphan of treatment; its median survival is only 3 to 4 months. Since 1999 we had demonstrated that gemcitabine (Gem) and gemcitabine-cisplatin (Gem-plat) are active regimens against this disease, but median survival increases to only 8 months. We had seen some complete responses and cases with impressive partial responses, but all of them are transients, recurrence appears in all pts. The benefit of combining CHTx and surgery had not been tested in MGBC, but has demonstrated promising results in others GI cancers. Methods: A retrospective analysis was performed in data from 9 patients (pts) who had liver resection for MGBC. Gem o gem-plat was given to all patients. Between September 1999 and July 2005 we had included more than 70 pts in two trials and others 25 pts had been treated outside of clinical trials. Among then, 9 patients with metastases from MGBC who were treated with Gem ± plat, were sent for resection of residual tumors. All pts received radio-chemotherapy after resection The primary endpoint was overall survival. Safety was a secondary end point. Results: We report the results of the first 9 patients with at least 9 months follow-up post surgery. Median overall survival is 17 months (9+ - 24). Only one pt is free of recurrence, (at 9 months), all others died due to relapse. Liver was the most frequent site of recurrence (8/8), but also peritoneal cavity and duodenum. All pts presented recurrence distant to initial tumor site. Most possible explanation for recurrence in 3 cases was R1 resection. In the CHTx phase no one pts required a dose reduction. Grade ≥3 was rare, vomiting in 2.0%, febrile neutropenia in 1.3%. There was no toxic death. Surgical complications (within 30 days of surgery) were low, with no one requiring reoperation, and no deaths were observed. Conclusions: Chemotherapy with Gem ± cisplatin was safely administered. Surgical mortality and morbidity rates were low. Even though a high proportion of patients died due to relapse, and thus suggest that this approach in inconvenient, this combined therapy offer a double life expectancy compare to chemotherapy alone. No significant financial relationships to disclose.
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
Authors: Rui-Hua Xu, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua, Weiguo Su
Journal: Journal of Hematology & Oncology (2017)

To assess the efficacy and safety of fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, in metastatic colorectal cancer (mCRC) patients. A phase Ib open-label study and phase II randomized, placebo-controlled trial compared the efficacy of fruquintinib plus best supportive care (BSC) with placebo plus BSC in mCRC patients with ≥2 lines of prior therapies. The primary endpoint was progression-free survival (PFS). In the phase Ib study, 42 patients took fruquintinib 5 mg for 3 weeks on/1 week off. The median PFS was 5.80 months, and the median overall survival (OS) was 8.88 months. In the phase II study, 71 patients were randomized (47 to fruquintinib, 24 to placebo). PFS was significantly improved with fruquintinib plus BSC (4.73 months; 95% confidence interval [CI] 2.86–5.59) versus placebo plus BSC (0.99 months; 95% CI 0.95–1.58); (hazard ratio [HR] 0.30; 95% CI 0.15–0.59; P < 0.001). The median OS was 7.72 versus 5.52 months (HR 0.71; 95% CI 0.38–1.34). The most common grade 3–4 adverse events were hypertension and hand-foot skin reaction. Fruquintinib showed a significant PFS benefit of 3.7 months in patients with treatment-refractory mCRC. The safety profile was consistent with that of VEGFR tyrosine kinase inhibitors. A randomized phase III confirmatory study in mCRC is underway. NCT01975077 and NCT02196688
Factors Predicting Outcome after Allogeneic Stem Cell Transplantation in Primary Refractory Acute Myeloid Leukemia: A Retrospective Analysis of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)
Authors: Elisabetta Todisco, Fabio Ciceri, Boschini Cristina, Fabio Giglio, Andrea Bacigalupo, Francesca Patriarca, Francesca Bonifazi, Irene Donnini, Emilio Paolo Alessandrino, William Arcese, Anna Paola Iori, Paola Marenco, Irene Cavattoni, Patrizia Chiusolo, Elisabetta Terruzzi, Luca Castagna, Armando Santoro, Elena Oldani, Barbara Bruno, Alberto Bosi, Alessandro Rambaldi
Journal: Blood (2014)
α4β7± Regulatory T Cells (Tregs) at Engraftment Predict Long-Term Graft-Versus-Host Disease (GVHD) Outcomes.
Authors: Brian G Engelhardt, Madan Jagasia, Michael T Rock, Adetola A. Kassim, Bipin N. Savani, Friedrich Schuening, James E Crowe
Journal: Blood (2009)
Prognostic Implications of Abdominal Computed Tomography at Diagnosis in Patients with Polycythemia Vera or Essential Thrombocythemia
Authors: Ik Chan Song, Jeong Eun Lee, Yoon Seok Choi, Ji Young Moon, Hyo Jin Lee, Hwan Jung Yun, Samyong Kim, Seung Woo Baek, Kyung Sook Shin, Deog-Yeon Jo
Journal: Blood (2015)
High-Sensitivity Troponin I Is Associated With High-Risk Plaque and MACE in Stable Coronary Artery Disease
Authors: Adam J. Brown, Anoop S.V. Shah, Nick E.J. West, Charis Costopoulos, Mateusz Orzalkiewicz, David E. Newby, Martin R. Bennett, Nicholas L. Mills, Patrick A. Calvert
Journal: JACC. Cardiovascular imaging (2017)
Methylation of H3K9 by G9a/GLP protects against pathological cardiac hypertrophy
Authors: Bernard Thienpont, Jan Aronsen, Emma Robinson, Hanneke Okkenhaug, Elena Loche, Ariana Ferrini, Patrick Brien, Kanar Alkass, Alessandro Tomasso, Asmita Agrawal, Olaf Bergmann, Ivar Sjaastad, Wolf Reik, Llewelyn Roderick
Journal: Journal of Clinical Investigation (2016)
Burkitt Lymphoma Specific Zinc Finger Protein ZNF385B Is Involved in Regulation of B Cell Apoptosis
Authors: Kazutoshi Iijima, Hiroyuki Yamada, Masashi Miharu, Atsuko Nakazawa, Junichiro Fujimoto, Kenichiro Kobayashi, Hajime Okita, Nobutaka Kiyokawa
Journal: Blood (2011)
Morphological Changes of Platelets from Patients with Von Willebrand Disease Types 2B and 3 Suggest That Von Willebrand Factor Intervenes in Platelet Formation from Megakaryocytes.
Authors: Paquita Nurden, Alan T Nurden, Jean-Max Pasquet, Jocelyne Enouf, Cécile Faurie-Bonnafous, Sylvia La Marca, Margherita Punzo, Luciano Baronciani, Augusto B. Federici
Journal: Blood (2008)
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends
Authors: Sergey O. Bachurin, Elena V. Bovina, Aleksey A. Ustyugov
Journal: Medicinal Research Reviews (2017)

Abstract Alzheimer's disease (AD) is characterized by a chronic and progressive neurodegenerative process resulting from the intracellular and extracellular accumulation of fibrillary proteins: beta‐amyloid and hyperphosphorylated Tau. Overaccumulation of these aggregates leads to synaptic dysfunction and subsequent neuronal loss. The precise molecular mechanisms of AD are still not fully understood but it is clear that AD is a multifactorial disorder and that advanced age is the main risk factor. Over the last decade, more than 50 drug candidates have successfully passed phase II clinical trials, but none has passed phase III. Here, we summarize data on current “anti‐Alzheimer's” agents currently in clinical trials based on findings available in the Thomson Reuters «Integrity» database, on the public website www.clinicaltrials.gov , and on database of the website Alzforum.org . As a result, it was possible to outline some major trends in AD drug discovery: (i) the development of compounds acting on the main stages of the pathogenesis of the disease (the so‐called “disease‐modifying agents”) — these drugs could potentially slow the development of structural and functional abnormalities in the central nervous system providing sustainable improvements of cognitive functions, which persist even after drug withdrawal; (ii) focused design of multitargeted drugs acting on multiple molecular targets involved in the pathogenesis of the disease; (3) finally, the repositioning of old drugs for new (anti‐Alzheimer's) application offers a very attractive approach to facilitate the completion of clinical trials.
Single-Dose Intracardiac Injection of Pro-Regenerative MicroRNAs Improves Cardiac Function After Myocardial Infarction
Authors: Pierluigi Lesizza, Giulia Prosdocimo, Valentina Martinelli, Gianfranco Sinagra, Serena Zacchigna, Mauro Giacca
Journal: Circulation Research (2017)

Recent evidence indicates that a few human microRNAs (miRNAs), in particular hsa-miR-199a-3p and hsa-miR-590-3p, stimulate proliferation of cardiomyocytes and, once expressed in the mouse heart using viral vectors, induce cardiac regeneration after myocardial infarction. Viral vectors, however, are not devoid of safety issues and, more notably, drive expression of the encoded miRNAs for indefinite periods of time, which might not be desirable in light of human therapeutic application.As an alternative to the use of viral vectors, we wanted to assess the efficacy of synthetic miRNA mimics in inducing myocardial repair after single intracardiac injection using synthetic lipid formulations.We comparatively analyzed the efficacy of different lipid formulations in delivering hsa-miR-199a-3p and hsa-miR-590-3p both in primary neonatal mouse cardiomyocytes and in vivo. We established a transfection protocol allowing persistence of these 2 mimics for at least 12 days after a single intracardiac injection, with minimal dispersion to other organs and long-term preservation of miRNA functional activity, as assessed by monitoring the expression of 2 mRNA targets. Administration of this synthetic formulation immediately after myocardial infarction in mice resulted in marked reduction of infarct size and persistent recovery of cardiac function.A single administration of synthetic miRNA-lipid formulations is sufficient to stimulate cardiac repair and restoration of cardiac function.
Acupuncture for pain and dysfunction after neck dissection: preliminary results of a randomized controlled trial
Authors: D. Pfister, A. Vickers, G. Deng, J. S. Lee, D. Garrity, N. Lee, D. Kraus, A. Shaha, J. Shah, B. R. Cassileth
Journal: Journal of Clinical Oncology (2008)

6016 Background: Standard treatments for pain/dysfunction after neck dissection (ND) for cancer often have disappointing efficacy. Acupuncture (AC) has demonstrated benefits in randomized trials for treating chronic musculoskeletal pain, including in the neck and shoulder. Uncontrolled trials suggest AC to be of potential benefit for xerostomia relief. Methods: Eligible patients (pts) were >3 months post ND and radiation; had pain/dysfunction [Constant-Murley (CM) score <70] attributed to ND. Pts were randomized to weekly AC versus usual care (eg, physical therapy, analgesia, and/or anti-inflammatory drugs, per patient preference/physician recommendation) for 4 weeks. To address both efficacy and reproducibility, standard and optional AC points were used. The primary endpoint was pain/dysfunction as measured by CM score (0–100, higher is better). The secondary endpoint of xerostomia relief was measured by the Xerostomia Inventory (XI, normalized to a 0–100 scale, lower is better). Results: 70 pts were randomized to either AC (n=34) or control (n=36). Median age: 59 years; female/male: 26/44; modified radical ND: 83%; squamous cell carcinoma: 60%. Endpoint data were incomplete in 12 pts, the most common reason being failure to complete their final assessment (6 of 12 pts, 3 on each arm). Mean baseline CM scores (AC: 41.9 versus usual care: 45.0) improved more in the AC group (difference between groups 11.0; 95% Confidence Interval (CI) 2.9, 19.2; p=0.009). More pts responded to treatment (33% or more improvement in CM score) in the AC group (39% versus 7%, p=0.004). AC produced greater improvement in reported xerostomia (difference in XI 5.8; 95% CI 0.9, 10.7; p=0.021), a benefit that persisted even when the analysis was limited to pts with high baseline scores. Conclusion: Significant reductions in pain, dysfunction, and xerostomia were observed in pts receiving AC versus usual care. Although further study is needed, these data support the potential role of AC in addressing post-ND pain and dysfunction, as well as xerostomia. (Supported by CA098792). No significant financial relationships to disclose.
Autologous Cytokine-Induced Killer Cells as Post-Transplant Cellular Immunotherapy.
Authors: Sally Arai, Kevin Sheehan, Sherry Moore, Ginna Laport, Laura Johnston, Robert Lowsky, David Miklos, Keith Goldstein, Wen-Kai Weng, Judith Shizuru, Sandra Horning, Robert Negrin
Journal: Blood (2007)
Sobuzoxane-Containing Regimens Show Promising Response As Salvage Therapy for Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS)
Authors: Ikuo Shimizu, Wataru Takeda, Takehiko Kirihara, Keijiro Sato, Yuko Fujikawa, Toshimitsu Ueki, Yuki Hiroshima, Masahiko Sumi, Mayumi Ueno, Naoaki Ichikawa, Hikaru Kobayashi
Journal: Blood (2012)
Tandem Auto-Allo in Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR).
Authors: Luca Castagna, Sabine Furst, Thomas Prébet, Jean El Cheikh, Aude Charbonnier, Catherine Faucher, Mohamad Mohty, Norbert Vey, Didier Blaise
Journal: Blood (2009)
Abstract 11492: Active Driving Force in Fontan Circulation: Assessment of Respiratory and Ventricular Functions in Single Ventricular Patients Using Wave Intensity
Authors: Takashi Honda, Keiichi Itatani, Atsushi Kitagawa, Hisashi Ando, Yayoi Nakahata, Norihiko Oka, Kagami Miyaji, Masahiro Ishii
Journal: Circulation (2012)

Background: In Fontan circulation, in addition to continuous blood flow dependent on cardiac output, active driving forces with respiration, ventricular diastole, and muscle pump of lower extremiti...
Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Performed after Two Cycles of Standard Chemotherapy (CT) on Treatment Outcome in Hodgkin Disease.
Authors: Andrea Gallamini, Luigi Rigacci, Francesco Merli, Pasquale Errico, Alessandro Levis, Alberto Biggi, Antonio Castagnoli, Silvia Tavera, Luca Nassi
Journal: Blood (2004)
Gene Expression-Based Chemical Genomics Identifies Valproic Acid to Revert the Oncogenic Effect of GATA1s In Down Syndrome Megakaryoblastic Leukemia.
Authors: Kirsten Heitmann, Zhe Li, Jan-Henning Klusmann, Basant Kumar Thakur, Jennifer Schöning, Jean-Pierre Bourquin, Stuart H. Orkin, Dirk Reinhardt
Journal: Blood (2010)
Biochemical and Functional Characterization of a Serum-Free rVWF Drug Candidate.
Authors: Peter L. Turecek, H. Peter Matthiessen, Artur Mitterer, Herbert Gritsch, Katalin Váradi, Barbara Plaimauer, Martin Purtscher, Wilfried Woehrer, Eva-Maria Muchitsch, Hans Peter Schwarz
Journal: Blood (2006)
BACOPP-D - An Etoposide-Free Dose-Escalated Polychemotherapy Regimen in Advanced Hodgkin Lymphoma.
Authors: Ralph Naumann, Katrin Wetzko, Annette Haenel, Kai Friedrichsen, Ernst Zschuppe, Helmuth Schmidt, Monic Dawel, Bettina Beuthien-Baumann, Uta Schwanebeck, Gerhard Ehninger, Mathias Haenel
Journal: Blood (2007)
Comparison of the Peripheral Blood Stem Cell Mobilization and Harvest after Each Consolidation Chemotherapy in Patients with Acute Myeloid Leukemia in First Complete Remission Who Underwent Autologous Stem Cell Transplantation.
Authors: Ho-Jin Shin, Joo Seop Chung, Young Jin Choi, Je-Jung Lee, Sang Kyun Sohn, Goon Jae Cho, Hyeoung-Joon Kim, Deok-Hwan Yang, Jin Ho Back
Journal: Blood (2005)
Combination of LPL/ADAM29 Ratio and ZAP Expression Can Replace IGVH Sequencing in the Majority of CLL.
Authors: Pablo Oppezzo, Yuri Vasconcelos, Catherine Settegrana, Dominique Jeannel, Francoise Vuiller, Martine Brissard, Eliza Yuriko, Sugano Kimura, Stephane Bechet, Gerard Dumas, Magali Legarff, Helene Merle-Beral, Mihoko Yamamoto, Guillaume Dighiero, Frederic Davi
Journal: Blood (2004)
Minimal Residual Disease Evaluation By Real-Time Quantitative Polymerase Chain Reaction for Wilms Tumor 1 Gene Expression and Multicolour Flow Cytometry, in Pediatric B Lineage Acute Lymphoblastic Leukemia
Authors: Neelam Varma, Sandeep R., Shano Naseem, Man Updesh Singh Sachdeva, Deepak Bansal, Subhash Varma, Pankaj Malhotra
Journal: Blood (2015)
Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic Avenue in Acute Myeloid Leukemia.
Authors: Sarit E. Assouline, Eftihia Cocolakis, Caroline Rousseau, Biljana Culjkovic, Nathalie Beslu, Abdellatif Amri, Stephen N. Caplan, Brian Leber, Denis-Claude Roy, Katherine L. B. Borden, Wilson H. Miller
Journal: Blood (2009)
CD38 Compared with ZAP-70 or Immmunoglobulin Mutation Status as Predictor of Disease Progression in Chronic Lymphocytic Leukemia.
Authors: Laura Z. Rassenti, Donna S. Neuberg, Michael J. Keating, John G. Gribben, Ian W. Flinn, Kanti R. Rai, John C. Byrd, Neil E. Kay, Thomas J. Kipps
Journal: Blood (2004)
International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease
Authors: David C. Fajgenbaum, Thomas S. Uldrick, Adam Bagg, Dale Frank, David Wu, Gordan Srkalovic, David Simpson, Amy Y. Liu, David Menke, Shanmuganathan Chandrakasan, Mary Jo Lechowicz, Raymond S. M. Wong, Sheila Pierson, Michele Paessler, Jean-François Rossi, Makoto Ide, Jason Ruth, Michael Croglio, Alexander Suarez, Vera Krymskaya, Amy Chadburn, Gisele Colleoni, Sunita Nasta, Raj Jayanthan, Christopher S. Nabel, Corey Casper, Angela Dispenzieri, Alexander Fosså, Dermot Kelleher, Razelle Kurzrock, Peter Voorhees, Ahmet Dogan, Kazuyuki Yoshizaki, Frits van Rhee, Eric Oksenhendler, Elaine S. Jaffe, Kojo S. J. Elenitoba-Johnson, Megan S. Lim
Journal: Blood (2017)
A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis
Authors: Jérôme Boursier, Victor de Ledinghen, Vincent Leroy, Rodolphe Anty, Sven Francque, Dominique Salmon, Adrien Lannes, Sandrine Bertrais, Frederic Oberti, Isabelle Fouchard-Hubert, Paul Calès
Journal: Journal of Hepatology (2017)
Impaired Glucose Homeostasis in First-Episode Schizophrenia
Authors: Toby Pillinger, Katherine Beck, Cristian Gobjila, Jacek G. Donocik, Sameer Jauhar, Oliver D. Howes
Journal: JAMA Psychiatry (2017)

Schizophrenia is associated with an increased risk of type 2 diabetes. However, it is not clear whether schizophrenia confers an inherent risk for glucose dysregulation in the absence of the effects of chronic illness and long-term treatment.To conduct a meta-analysis examining whether individuals with first-episode schizophrenia already exhibit alterations in glucose homeostasis compared with controls.The EMBASE, MEDLINE, and PsycINFO databases were systematically searched for studies examining measures of glucose homeostasis in antipsychotic-naive individuals with first-episode schizophrenia compared with individuals serving as controls.Case-control studies reporting on fasting plasma glucose levels, plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin levels, insulin resistance, and hemoglobin A1c (HbA1c) levels in first-episode antipsychotic-naive individuals with first-episode schizophrenia compared with healthy individuals serving as controls. Two independent investigators selected the studies.Two independent investigators extracted study-level data for a random-effects meta-analysis. Standardized mean differences in fasting plasma glucose levels, plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin levels, insulin resistance, and HbA1c levels were calculated. Sensitivity analyses examining the effect of body mass index, diet and exercise, race/ethnicity, and minimal (≤2 weeks) antipsychotic exposure were performed.Of 3660 citations retrieved, 16 case-control studies comprising 15 samples met inclusion criteria. The overall sample included 731 patients and 614 controls. Fasting plasma glucose levels (Hedges g = 0.20; 95% CI, 0.02 to 0.38; P = .03), plasma glucose levels after an oral glucose tolerance test (Hedges g = 0.61; 95% CI, 0.16 to 1.05; P = .007), fasting plasma insulin levels (Hedges g = 0.41; 95% CI, 0.09 to 0.72; P = .01), and insulin resistance (homeostatic model assessment of insulin resistance) (Hedges g = 0.35; 95% CI, 0.14 to 0.55; P = .001) were all significantly elevated in patients compared with controls. However, HbA1c levels (Hedges g = -0.08; CI, -0.34 to 0.18; P = .55) were not altered in patients compared with controls.These findings show that glucose homeostasis is altered from illness onset in schizophrenia, indicating that patients are at increased risk of diabetes as a result. This finding has implications for the monitoring and treatment choice for patients with schizophrenia.
Abrogation of MLL-AF10 and CALM-AF10 Mediated Transformation Through Genetic Inactivation or Pharmacological Inhibition of the H3K79 Methyltransferase DOT1L.
Authors: Liying Chen, Aniruddha J Deshpande, Deepti Banka, Bernt Kathrin, Stuart Dias, Christian Buske, Edward J Olhava, Scott R Daigle, Victoria M Richon, Roy M Pollock, Scott A. Armstrong
Journal: Blood (2012)
Role of BRAF Mutations in Hematopoietic Malignancies and the Induction of Cytokine-Independence-Synergy with PI3K/Akt Pathway.
Authors: Massimo Libra, Maria C. Mazzarino, Valli De Re, Linda S. Steelman, Steven L. Abrams, Fred E. Bertrand, John G. Shelton, Sarah Molton, Martin McMahon, James A. McCubrey
Journal: Blood (2005)
Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort
Authors: Jennifer R Brown, Laura Rassenti, Donna Neuberg, Andrew Greaves, John C. Byrd, Michael R Grever, John G. Gribben, Neil E. Kay, Michael Keating, Kanti R. Rai, William G. Wierda, Thomas J Kipps
Journal: Blood (2008)
CD34+ Cobblestone Area-Forming Cells Are a Valuable Indicator to Screen the Soluble Inhibitors of Hematopoiesis in the Serum of Aplastic Anemia and MDS Patients.
Authors: Shohei Kikuchi, Masayoshi Kobune, Kazuyuki Murase, Satoshi Iyama, Tsutomu Sato, Yutaka Kawano, Koji Miyanishi, Yasushi Sato, Rishu Takimoto, Junji Kato
Journal: Blood (2009)
Hematopoietic Differentiation of ES Cells from P230 Bcr/Abl Transgenic Mouse.
Authors: Sakae Tanosaki, Koiti Inokuchi, Kazuhiro Sawaguchi, Jyunko Takeuchi, Masato Tamai, Naoya Uchida, Ayako Watanabe, Mituharu Inami, Hiroki Yamaguchi, Kazuo Dan
Journal: Blood (2005)